Zolset-D Capsule SR is a combination medication containing Domperidone 30mg and Rabeprazole 20mg, formulated for sustained release to provide effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and gastric discomfort. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting healing of acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of Domperidone and Rabeprazole in Zolset-D Capsule SR addresses both motility and acid secretion abnormalities, making it suitable for patients experiencing dyspepsia, reflux symptoms, and delayed gastric emptying. This combination is particularly beneficial in cases where acid suppression alone is insufficient to control symptoms. Zolset-D Capsule SR should be administered as prescribed by a healthcare professional, with consideration of contraindications such as hypersensitivity to components, prolactinoma, or cardiac arrhythmias. Caution is advised in patients with hepatic impairment or those taking medications that may interact with Domperidone or Rabeprazole. Regular monitoring and adherence to dosage instructions enhance therapeutic outcomes and minimize adverse effects.